BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Osel, Inc. In-licenses Therapeutic Drug Product From Japan


10/19/2005 5:12:54 PM

SANTA CLARA, Calif., March 2 /PRNewswire/ -- Osel, Inc., the Bacterio-Therapeutics company, has signed a definitive in-licensing agreement for MIYA-BM(R), an oral therapeutic drug product from Miyarisan Pharmaceutical Company, Ltd. of Japan. Osel has exclusive rights to commercialize the product in North America and Europe.

MIYA-BM(R), an oral tablet, was approved by the Japanese Ministry of Health, Labor and Welfare, for the indications of C. difficile associated disease (CDAD) and the larger market of antibiotic associate diarrhea (AAD). "This product complements our current portfolio of drug product candidates as it is also a comensal live bacterial product for the treatment of infections for which no optimal treatment exists today. Billions of dollars are expended in the treatment and extended hospital stays resulting from these infections," said Osel president, Ralph Levy.

The active ingredient is a specific, proprietary strain of C. butyricum, which has been shown to prevent as well as treat, the antibiotic-induced gastrointestinal disorders, AAD and CDAD. It has been used safely and effectively in thousands of patients, from pediatric to geriatric, for these indications for years in other countries, including Japan. The product is manufactured by a proprietary process at Miyarisan's state-of-the-art biological manufacturing facility located in Nagano, Japan.

"It is a privilege to work with Miyarisan, a well organized and extremely professional organization, in the commercialization of this product to solve this unmet medical need in the large North American and European markets." said Mr. Levy. Osel is planning pivotal clinical trials first in the U.S. and then in Europe, and is currently designing the clinical trial protocol for these studies. "This agreement works very much in the strategic interest of our two companies, and after regulatory approval will enable MIYA-BM(R) to be effectively used in other major markets," said Masayuki Uchida, Miyarisan's president.

The incidence of AAD ranges from 3.2 to 29 per 100 hospitalized patients per year. AAD typically extends patients' hospital stays 8 to 20 days, resulting in higher medical care costs and a higher risk of acquiring other types of nosocomial infections. Treatment for AAD is limited because there are no approved therapies available apart from discontinuation of the inciting antibiotic and supportive care. Discontinuation of antibiotic therapy is effective in only 15% of patients. Toxigenic C. difficile is responsible for 20% to 30% of AAD cases. This organism is the cause of pseudomembranous colitis, a potentially life threatening condition, and the most common intestinal tract infection in adult hospitalized patients. Diarrhea and colitis of CDAD are mediated by two toxins produced by toxigenic C. difficile strains. CDAD is currently treated with metronidazole or vancomycin. Although these antibiotics effectively kill C. difficile, they also disrupt the protective gut flora. Recurrence of CDAD from re-infection with C. difficile is a major medical problem in the hospital setting, and occurs in 15% to 20% of patients within 30 days of discontinuing antibiotic therapy.

About Osel

Osel, Inc. is the leading company in the emerging field of Bacterio-Therapeutics. The company's business is based on exploiting recent scientific discoveries demonstrating the central role of naturally occurring mucosal bacteria in the maintenance of health and the prevention of disease. Osel's mission is to harness the protective properties of these specialized non-pathogenic bacteria as a basis for a series of innovative products initially targeted for the prevention and treatment of diseases of the genitourinary and gastrointestinal tracts.

Contact: Ralph Levy President, Osel Inc. Phone: 408-986-0012 ext. 206 Cell : 415-699-0135 Email: rlevy@oselinc.com

Osel, Inc.

CONTACT: Ralph Levy, President of Osel Inc., +1-408-986-0012 ext. 206,or cell, +1-415-699-0135, or rlevy@oselinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES